BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Echo Street Capital Management LLC | 4,090 | $278,406 | 0.00% |
CAPSTONE INVESTMENT ADVISORS, LLC | 8,535 | $580,977 | 0.00% |
West Tower Group, LLC | 94 | $6,399 | 0.00% |
PICTON MAHONEY ASSET MANAGEMENT | 1,645 | $112 | 0.00% |
Castleview Partners, LLC | 55 | $3,744 | 0.00% |
Janney Montgomery Scott LLC | 10,329 | $703 | 0.00% |
Tradition Wealth Management, LLC | 424 | $29 | 0.00% |
BANK OF AMERICA CORP /DE/ | 436,833 | $29,735,240 | 0.00% |
BESSEMER GROUP INC | 19,653 | $1,339 | 0.00% |
BANK OF NOVA SCOTIA | 14,613 | $994,707 | 0.00% |
Rathbones Group PLC | 5,541 | $377,175 | 0.00% |
NATIONAL BANK OF CANADA /FI/ | 33,630 | $2,258,254 | 0.00% |
SIGNATUREFD, LLC | 1,851 | $125,998 | 0.00% |
DekaBank Deutsche Girozentrale | 20,880 | $1,415 | 0.00% |
CAPITAL FUND MANAGEMENT S.A. | 10,794 | $734,747 | 0.00% |
TRUIST FINANCIAL CORP | 20,077 | $1,366,616 | 0.00% |
Alberta Investment Management Corp | 3,100 | $211,017 | 0.00% |
CENTRAL TRUST Co | 988 | $67,254 | 0.00% |
CREDIT AGRICOLE S A | 1,481 | $100,812 | 0.00% |
HighTower Advisors, LLC | 18,866 | $1,290,000 | 0.00% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q3 2023. To view BIO-TECHNE CORP's shareholder history, click here.